

SAMPLE TEMPLATE FOR DATA COLLECTION													Date of Publication: 30/06/2025		
	Full name	Practice or business address			Unique Country Identifier OPTIONAL	Donations and Grants to HCOs (§ 7 Abs. 2 Nr. 2a)	Contribution to costs of Events (§ 7 Abs. 2 Nr.1 a) (i) und (ii) & § 7 Abs. 2 Nr. 2 b) (i), (ii) und (iii))			Fee for service and consultancy (§ 7 Abs. 2 Nr. 1 b) & § 7 Abs. 2 Nr. 2 c))			Total Optional		
		City	Country	Address			Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Reimbursement of expenses				
	(§ 8 Abs.1 Nr. 1)	(§ 8 Abs. 1 Nr. 2)	(§ 8 Abs. 1 Nr. 2)	(§ 8 Abs. 1 Nr. 2)	(§ 8 Abs. 1 Nr. 3) (falls vorhanden)										
HCPs	INDIVIDUAL NAMED DISCLOSURE – one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)														
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons														
	Aggregate amount attributable to transfers of value to such Recipients - § 7 Abs. 6														
	Number of Recipients in aggregate disclosure - § 7 Abs. 6														
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - § 7 Abs. 6														
HCOs															
	Société Luxembourgeoise de néphrologie(SLN)	Esch-Sur-Alzette	Luxembourg	80 Rue Jean-Pierre Michels			3000.00						3000.00		
	Société Luxembourgeoise d'Oncologie	Strassen	Luxembourg	1A-B Rue Thomas Edison			5750.00						5750.00		
	Aggregate amount attributable to transfers of value to such Recipients - § 7 Abs. 6														
	Number of Recipients in aggregate disclosure - § 7 Abs. 6														
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - § 7 Abs. 6														
R & D	AGGREGATE DISCLOSURE														
	Transfers of Value re Research & Development as defined , § 7 Abs. 5												0.00		